Rein Therapeutics Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
RNTX Nasdaq 2834 www.reintx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Rein Therapeutics Inc.

Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress - Sep 4th, 2026 6:00 am
Here's Why You Should Add RNTX Stock to Your Portfolio Now - Sep 3rd, 2026 9:01 am
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis - Aug 20th, 2026 6:00 am
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Aug 14th, 2026 4:44 am
Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications - Aug 4th, 2026 6:00 am
Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries - Jul 21st, 2026 6:00 am
All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy - Jun 17th, 2026 10:00 am
Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom - Jun 11th, 2026 6:00 am
Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option - May 18th, 2026 6:00 am
Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock - Apr 30th, 2026 6:00 pm
Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis - Apr 29th, 2026 6:00 am
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis - Mar 3rd, 2026 6:00 am
Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis - Jan 20th, 2026 6:00 am
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis - Oct 9th, 2025 5:30 am